Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$73.69 USD

73.69
3,674,571

+0.39 (0.53%)

Updated Jul 18, 2024 02:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in Store for Ligand (LGND) This Earnings Season?

by Zacks Equity Research

Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.

    Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More

    by Zacks Equity Research

    Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.

    Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More

    by Zacks Equity Research

    Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.

    Lilly (LLY) Q3 Earnings & Revenues Lag Estimates, Stock Down

    by Zacks Equity Research

    Eli Lilly (LLY) misses on both earnings and sales for the third quarter. The company reiterates its revenue guidance for 2020.

    Should You Buy Gilead (GILD) Ahead of Earnings?

    by Zacks Equity Research

    Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day

    by Zacks Equity Research

    Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day

    Will Covid-Led Higher Demand Aid Teladoc's (TDOC) Q3 Earnings?

    by Zacks Equity Research

    A surge in demand for virtual health care services is likely to have contributed to Teladoc's (TDOC) earnings in Q3

    Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?

    by Zacks Equity Research

    On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.

    Werner, Carlisle, Gilead, Intel and Mattel as Zacks Bull and Bear of the Day

    by Zacks Equity Research

    Werner, Carlisle, Gilead, Intel and Mattel as Zacks Bull and Bear of the Day

    Sweta Killa headshot

    Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

    by Sweta Killa

    The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

    Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?

    by Zacks Equity Research

    Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports third-quarter 2020 results.

    Mark Vickery headshot

    Stimulus or No? Plus News from GILD, Earnings from INTC & MAT

    by Mark Vickery

    Gilead (GILD) shares are up 4% in late trading on an announcement that the FDA has granted full approval to its remdesivir treatment.

    Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates

    by Zacks Equity Research

    The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.

    Sweta Killa headshot

    Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

    by Sweta Killa

    The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

    Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

    by Zacks Equity Research

    Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?

    by Zacks Equity Research

    Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.

    Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Gilead Sciences (GILD) closed at $60.55, marking a -0.03% move from the previous day.

    Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion

    by Zacks Equity Research

    Gilead (GILD) gets positive CHMP opinion for KTE-X19, a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma.

    Neena Mishra headshot

    Why You Should Invest in Genomics ETFs

    by Neena Mishra

    Genomics ETFs have surged of late; here's why

    Regeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval

    by Zacks Equity Research

    Regeneron (REGN) gets FDA nod for its triple antibody cocktail for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients.

    Mark Vickery headshot

    Stocks Down 2nd Straight Day: Prime, Lilly, United Q3 & More

    by Mark Vickery

    Market indexes closed lower for their second-straight session, following a string of four days in a row higher.

    Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates

    by Zacks Equity Research

    Regeneron (REGN) and Gilead (GILD) continue to be in the spotlight on coronavirus-related updates.

    Lilly's Coronavirus Antibody Study Paused on Safety Concerns

    by Zacks Equity Research

    Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.

    Gilead Sciences (GILD) Stock Moves -0.09%: What You Should Know

    by Zacks Equity Research

    Gilead Sciences (GILD) closed at $64.49 in the latest trading session, marking a -0.09% move from the prior day.

    Gilead & Galapagos Announce Positive Data on UC Candidate

    by Zacks Equity Research

    Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.